Piper Sandler keeps Pelthos Therapeutics at Overweight, cuts price target to $21 from $48
Piper Sandler kept its Overweight rating on Pelthos Therapeutics and cut its price target by 56.2%, to $21 from $48, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Piper Sandler maintained its Overweight rating on Pelthos Therapeutics but lowered its price target to $21 from $48, a 56.2% decrease, according to TradingView. The source cites reference data provided by Benzinga.
The revised target implies an upside of 161.5% from the November 12 close of $8.03. The report does not give a reason for the change, and it states clearly that it is not an investment recommendation.
Target revisions of this size often reflect an update to a valuation model rather than new public events at the company.
why it matters
For the market, this is mainly a signal that one brokerage has reassessed the stock's valuation. A target change alone, without new company data, usually has little effect on the share price or the broader market.
tags
instruments
sources
- Piper Sandler maintains Crescent Biopharma at Overweight, lowers price target to $32 from $35 — TradingView, 13 November 2026 at 15:54 UTC
- Piper Sandler maintains Pelthos Therapeutics at Overweight, lowers price target to $21 from $48 — TradingView, 13 November 2026 at 15:59 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗